Linked Data API

Show Search Form

Search Results

1132764
star this property registered interest false more like this
star this property date less than 2019-06-18more like thismore than 2019-06-18
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text What progress the Government has made on making medical cannabis available to people who need it. more like this
star this property tabling member constituency Gower more like this
star this property tabling member printed
Tonia Antoniazzi more like this
star this property uin 911421 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-18more like thismore than 2019-06-18
star this property answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> more like this
star this property answering member constituency West Suffolk more like this
star this property answering member printed Matt Hancock more like this
star this property question first answered
less than 2019-06-18T16:50:49.883Zmore like thismore than 2019-06-18T16:50:49.883Z
star this property answering member
4070
star this property label Biography information for Matt Hancock more like this
unstar this property tabling member
4623
unstar this property label Biography information for Tonia Antoniazzi more like this
1132025
star this property registered interest false more like this
star this property date less than 2019-06-13more like thismore than 2019-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how and by whom medical cannabis was produced in the UK before its legalisation. more like this
star this property tabling member constituency Central Ayrshire more like this
star this property tabling member printed
Dr Philippa Whitford more like this
star this property uin 264425 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-18more like thismore than 2019-06-18
star this property answer text <p>Prior to the change of the law on 1 November 2018, only cannabis-based products that had been given a marketing authorisation (product licence) by the medicines regulators, the Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency could be prescribed. Before issuing a marketing authorisation the MHRA accesses all the available evidence on efficacy and safety arising out of pre-clinical research and clinical trials and evidence and information supplied by the manufacturer. The regulators also inspect the factory where the medicine is to be made, to make sure that supplies will be of a uniformly and consistently high standard.</p><p> </p><p>The following cannabis-based products and related products received a marketing authorisation in the United Kingdom/European Union before 1 November 2018:</p><p> </p><p>- Sativex - (produced by GW Pharmaceuticals) containing tetrahydrocannabinol (THC) and cannabidiol - holds a licence for spasticity in multiple sclerosis; and</p><p>- Nabilone - (multiple manufacturers) which contains a synthetic, non-natural cannabinoid which mimics THC, holds a marketing authorisation for nausea and vomiting caused by chemotherapy.</p><p> </p><p>In addition, Epidiolex (also produced by GW Pharmaceuticals from cannabis) for two severe forms of intractable epilepsy (Lennox-Gastaut Syndrome or Dravet Syndrome), is currently being considered for a marketing authorisation by the European Medicines Agency.</p><p> </p><p>The change in the law allows the prescription, by specialist doctors on the General Medical Council’s Specialist Register, of cannabis-based products that have not been through this rigorous process but that meet certain quality standards in cases where all licensed products have been considered and discounted and it is in the best interest of the patient. It also makes</p><p>it easier and will incentivise further research into the potential health benefits of cannabis-based products and the development of further licensed products for more routine use in the health service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-18T16:31:54.17Zmore like thismore than 2019-06-18T16:31:54.17Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
4385
unstar this property label Biography information for Dr Philippa Whitford more like this
1131293
star this property registered interest false more like this
star this property date less than 2019-06-11more like thismore than 2019-06-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS. more like this
star this property tabling member constituency Ross, Skye and Lochaber more like this
star this property tabling member printed
Ian Blackford more like this
star this property uin 263171 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-19more like thismore than 2019-06-19
star this property answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-19T09:39:54.803Zmore like thismore than 2019-06-19T09:39:54.803Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
4390
unstar this property label Biography information for Ian Blackford more like this
1128815
star this property registered interest false more like this
star this property date less than 2019-06-03more like thismore than 2019-06-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all patients who would benefit from medical cannabis are able to access that treatment on prescription on the NHS. more like this
star this property tabling member constituency Birkenhead more like this
star this property tabling member printed
Frank Field more like this
star this property uin 259011 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-11more like thismore than 2019-06-11
star this property answer text <p>Cannabis-based products for medicinal use are no different from other medicines, and existing systems for the funding of both licensed and unlicensed medicines apply.</p><p>Any medicines which receive a marketing authorisation from the Medicines and Healthcare Products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by the National Institute for Health and Care Excellence. This is the foundation of National Health Service decisions about routine funding, and applies to all licensed medicines. For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS Trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care has heard patients report difficulties in accessing medicinal cannabis. As a result, he asked the Department to work closely with NHS England to undertake a rapid process evaluation. This is underway and will review NHS system processes to identify and make recommendations to address any barriers to clinically appropriate prescribing, should they exist.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-11T16:52:22.153Zmore like thismore than 2019-06-11T16:52:22.153Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
478
unstar this property label Biography information for Frank Field more like this
1129369
star this property registered interest false more like this
star this property date less than 2019-06-03more like thismore than 2019-06-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what discussions his Department has had with (a) NHS England, (b) manufacturers and (c) NICE on funding arrangements for accessing (a) licensed and (b) unlicensed cannabis-based medicines on the NHS. more like this
star this property tabling member constituency Dudley North more like this
star this property tabling member printed
Ian Austin more like this
star this property uin 259109 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-11more like thismore than 2019-06-11
star this property answer text <p>In developing policy on the rescheduling of cannabis-based products for medicinal use, the Government has applied existing arrangements for accessing licensed and unlicensed medicines on the National Health Service. The Department has not had discussions with NHS England, manufacturers or the National Institute for Health and Care Excellence (NICE) on funding arrangements for accessing licensed or unlicensed cannabis-based products, beyond the existing arrangements.</p><p>The recent changes to the law to reschedule cannabis-based products for medicinal use, does not impact on the availability of existing licensed cannabis-based medicinal products, such as Sativex and Nabilone. Any medicines which receive a marketing authorisation from the Medicines and Healthcare products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by NICE. This is the foundation of NHS decisions about routine funding, and applies to all licensed medicines.</p><p>For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-11T16:54:00.047Zmore like thismore than 2019-06-11T16:54:00.047Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1511
unstar this property label Biography information for Ian Austin more like this
1128441
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 257705 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-10more like thismore than 2019-06-10
star this property answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-10T13:23:02.387Zmore like thismore than 2019-06-10T13:23:02.387Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1128442
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 257706 more like this
unstar this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2019-06-10more like thismore than 2019-06-10
star this property answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-10T13:18:03.37Zmore like thismore than 2019-06-10T13:18:03.37Z
star this property question first ministerially corrected
less than 2019-06-11T11:31:21.83Zmore like thismore than 2019-06-11T11:31:21.83Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property previous answer version
121340
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1128443
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when he plans to publish the interim report produced by NHS England to identify the barriers that are blocking access to prescribed medicinal cannabis by patients. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 257707 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-07more like thismore than 2019-06-07
star this property answer text <p>The NHS England process review is underway and interviews are scheduled to take place over June 2019. The interim report will not be published, as by its nature any findings will be incomplete. The Government is, however, committed to publishing a summary of the final findings and recommendations before summer recess.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 257708 more like this
star this property question first answered
less than 2019-06-07T14:49:30.61Zmore like thismore than 2019-06-07T14:49:30.61Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1128444
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when he plans to publish the final report by NHS England to identify the barriers that are blocking access to prescribed medicinal cannabis by patients. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 257708 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-07more like thismore than 2019-06-07
star this property answer text <p>The NHS England process review is underway and interviews are scheduled to take place over June 2019. The interim report will not be published, as by its nature any findings will be incomplete. The Government is, however, committed to publishing a summary of the final findings and recommendations before summer recess.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 257707 more like this
star this property question first answered
less than 2019-06-07T14:49:30.657Zmore like thismore than 2019-06-07T14:49:30.657Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1128521
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 36, what the timetable is for making available a public register of specialist clinicians who can prescribe cannabis-based medicines. more like this
star this property tabling member constituency Dudley North more like this
star this property tabling member printed
Ian Austin more like this
star this property uin 257698 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-05more like thismore than 2019-06-05
star this property answer text <p>The law provides that specialist clinicians on the General Medical Council’s ‘Specialist Register’ can prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>A general practitioner (GP) may make a referral to a specialist clinician on the General Medical Council’s ‘Specialist Register’ once the patient reaches the appropriate point in their treatment pathway.</p><p>A list of Registered Medical Practitioners, including specialist clinicians, is available at the following link:</p><p><a href="https://www.gmc-uk.org/registration-and-licensing/the-medical-register" target="_blank">https://www.gmc-uk.org/registration-and-licensing/the-medical-register</a></p><p> </p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-05T13:48:29.21Zmore like thismore than 2019-06-05T13:48:29.21Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
unstar this property tabling member
1511
unstar this property label Biography information for Ian Austin more like this